Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

84 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of nonalcoholic fatty liver disease (NAFLD) in severe obesity using noninvasive tests and imaging techniques.
Theel W, Boxma-de Klerk BM, Dirksmeier-Harinck F, van Rossum EFC, Kanhai DA, Apers J, van Dalen BM, de Knegt RJ, Holleboom AG, Tushuizen ME, Grobbee DE, Wiebolt J, Castro Cabezas M. Theel W, et al. Among authors: holleboom ag. Obes Rev. 2022 Aug;23(8):e13481. doi: 10.1111/obr.13481. Epub 2022 Jun 12. Obes Rev. 2022. PMID: 35692179 Review.
[Non-alcoholic fatty liver disease; a full-bodied epidemic].
Tushuizen ME, Holleboom AG, Koot BGP, Blokzijl H, van Mil SWC, Koek GH. Tushuizen ME, et al. Among authors: holleboom ag. Ned Tijdschr Geneeskd. 2020 Feb 27;164:D4096. Ned Tijdschr Geneeskd. 2020. PMID: 32267638 Dutch.
A global survey of health care workers' awareness of non-alcoholic fatty liver disease: The AwareNASH survey.
Driessen S, de Jong VD, van Son KC, Klompenhouwer T, Colardelle Y, Alings M, Moreno C, Anker SD, Castro Cabezas M, Holleboom AG, Grobbee DE, Tushuizen ME. Driessen S, et al. Among authors: holleboom ag. United European Gastroenterol J. 2023 Sep;11(7):654-662. doi: 10.1002/ueg2.12445. Epub 2023 Aug 10. United European Gastroenterol J. 2023. PMID: 37563849 Free PMC article.
Metabolic dysfunction-associated steatotic liver disease and the heart.
Driessen S, Francque SM, Anker SD, Castro Cabezas M, Grobbee DE, Tushuizen ME, Holleboom AG. Driessen S, et al. Among authors: holleboom ag. Hepatology. 2023 Dec 25. doi: 10.1097/HEP.0000000000000735. Online ahead of print. Hepatology. 2023. PMID: 38147315
Prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) in a middle-aged population with overweight and normal liver enzymes, and diagnostic accuracy of noninvasive proxies.
van Son KC, Te Nijenhuis-Noort LC, Boone SC, Mook-Kanamori DO, Holleboom AG, Roos PR, Lamb HJ, Alblas G, Coenraad MJ, Rosendaal FR, de Mutsert R, Tushuizen ME. van Son KC, et al. Among authors: holleboom ag. Medicine (Baltimore). 2024 Jan 5;103(1):e34934. doi: 10.1097/MD.0000000000034934. Medicine (Baltimore). 2024. PMID: 38181294 Free PMC article.
Intrapancreatic fat deposition is unrelated to liver steatosis in metabolic dysfunction-associated steatotic liver disease.
Mak AL, Wassenaar N, van Dijk AM, Troelstra M, Houttu V, van Son K, Driessen S, Zwirs D, van den Berg-Faay S, Shumbayawonda E, Runge J, Doukas M, Verheij J, Beuers U, Nieuwdorp M, Cahen DL, Nederveen A, Gurney-Champion O, Holleboom A. Mak AL, et al. JHEP Rep. 2024 Jan 1;6(3):100998. doi: 10.1016/j.jhepr.2023.100998. eCollection 2024 Mar. JHEP Rep. 2024. PMID: 38379586 Free PMC article.
Prevalence and predictive features of metabolic dysfunction-associated steatotic liver disease in type 1 diabetes.
Fuhri Snethlage CM, Meijnikman AS, Mak AL, Rampanelli E, Voermans B, Callender CAK, de Groen P, Roep BO, van Raalte DH, Knop FK, Holleboom AG, Nieuwdorp M, Hanssen NMJ. Fuhri Snethlage CM, et al. Among authors: holleboom ag. Eur J Endocrinol. 2024 Apr 29:lvae043. doi: 10.1093/ejendo/lvae043. Online ahead of print. Eur J Endocrinol. 2024. PMID: 38679966
Implementation of a liver health check in people with type 2 diabetes.
Abeysekera KWM, Valenti L, Younossi Z, Dillon JF, Allen AM, Nourredin M, Rinella ME, Tacke F, Francque S, Ginès P, Thiele M, Newsome PN, Guha IN, Eslam M, Schattenberg JM, Alqahtani SA, Arrese M, Berzigotti A, Holleboom AG, Caussy C, Cusi K, Roden M, Hagström H, Wong VW, Mallet V, Castera L, Lazarus JV, Tsochatzis EA. Abeysekera KWM, et al. Among authors: holleboom ag. Lancet Gastroenterol Hepatol. 2024 Jan;9(1):83-91. doi: 10.1016/S2468-1253(23)00270-4. Lancet Gastroenterol Hepatol. 2024. PMID: 38070521 Review.
Can liver stiffness measurement accurately predict disease progression and clinical outcome in patients with metabolic dysfunction-associated steatotic liver disease and bridging fibrosis or cirrhosis?
van Doorn DJ, Holleboom AG, Takkenberg RB, Verheij J, Lantinga MA. van Doorn DJ, et al. Among authors: holleboom ag. Hepatobiliary Surg Nutr. 2023 Dec 1;12(6):912-915. doi: 10.21037/hbsn-23-445. Epub 2023 Oct 30. Hepatobiliary Surg Nutr. 2023. PMID: 38115935 Free PMC article. No abstract available.
Anaerobutyricum soehngenii Reduces Hepatic Lipogenic Pathways and Increases Intestinal Gluconeogenic Gene Expression in Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD) Mice.
Mak AL, Augustijn QJJ, Heymann CJF, Havik S, Verdoes X, Rios-Morales M, Bosmans LA, Verheij J, Meijnikman AS, de Jonge PA, Herrema H, de Vos WM, Nieuwdorp M, Grefhorst A, Holleboom AG. Mak AL, et al. Among authors: holleboom ag. Int J Mol Sci. 2024 Mar 20;25(6):3481. doi: 10.3390/ijms25063481. Int J Mol Sci. 2024. PMID: 38542455 Free PMC article.
84 results